{"entity":{"id":"nct05968326","kind":"trial","name":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC","aka":["IMCODE003"],"tldr":"A phase 2 trial of Autogene cevumeran and Atezolizumab in pancreatic ductal adenocarcinoma, run by Genentech, Inc., active and no longer recruiting.","summary":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC is a phase 2 interventional study registered as NCT05968326 by Genentech, Inc., with 260 participants enrolled, started 2023-10-18 and due to reach its primary completion in 2031-01-01. Interventions recorded: Autogene cevumeran, Atezolizumab and mFOLFIRINOX.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05968326","url":"https://clinicaltrials.gov/study/NCT05968326"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","resectable-pdac"],"sections":[],"technologies":["checkpoint-inhibitor","neoantigen-mrna-vaccine"],"targets":[],"drugs":["autogene-cevumeran","atezolizumab"],"companies":["flatiron-health","biontech"],"institutions":[],"pathways":[],"terms":["pancreatic-trials-open-today"],"trials":["autogene-cevumeran-phase-1","amplify-7p"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["IMCODE003 (registry, 24 September 2026): randomised phase 2 of adjuvant autogene cevumeran with atezolizumab and modified FOLFIRINOX against modified FOLFIRINOX alone in resected pancreatic ductal adenocarcinoma, 260 participants (estimated), active but no longer recruiting, started 18 October 2023, primary completion (disease-free survival) January 2031; sites in ten countries. UK sites (8): Clatterbridge Liverpool, Belfast City Hospital, University Hospitals Birmingham, Addenbrooke's Cambridge, Barts Health, Guy's Hospital, Hammersmith (Imperial) and University College London Cancer Institute."],"nct":"NCT05968326","phase":"2","setting":"A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma","sponsor":"Genentech, Inc.","started":"2023-10-18","startedType":"actual","enrolled":260,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05968326/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"autogene-cevumeran","kind":"drug","name":"Autogene cevumeran","route":"/drugs/autogene-cevumeran/"}],"company":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"},{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}],"trial":[{"id":"amplify-7p","kind":"trial","name":"AMPLIFY-7P","route":"/trials/amplify-7p/"},{"id":"autogene-cevumeran-phase-1","kind":"trial","name":"Autogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering)","route":"/trials/autogene-cevumeran-phase-1/"}],"paper":[{"id":"paper-prodige-24-five-year-outcomes-jama-oncol-2022","kind":"paper","name":"Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-prodige-24-five-year-outcomes-jama-oncol-2022/"},{"id":"paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025","kind":"paper","name":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","route":"/key-papers/paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025/"}],"roadmap":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"}]}}